Current status and advances in ultrasound-guided thermal ablation for hepatocellular carcinoma

Xin LI; Ping LIANG

doi:10.3969/j.issn.1001-5256.2021.03.004

Volume 37 Issue 3

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(3): 510-514

PDF( 1971 KB)

Current status and advances in ultrasound-guided thermal ablation for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.03.004

Xin LI,
Ping LIANG^,

Department of Interventional Ultrasound, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

Received Date: 2020-11-21
Accepted Date: 2020-11-21
Published Date: 2021-03-20

Abstract

Abstract

Hepatocellular carcinoma (HCC) is a common malignant tumor in clinical practice, and image-guided thermal ablation is a radical treatment method for early-stage HCC and a method for palliative tumor reduction and combination with systematic therapy for advanced HCC. With the advantages of real-time imaging, accurate guiding, easy operation, portability, low cost, no radiation damage, and high efficiency, ultrasound plays an important role in preoperative planning, intraoperative guiding, postoperative evaluation, and long-term follow-up in thermal ablation for HCC. With the advances in ultrasound and imaging fusion technology and the development of functional imaging technology represented by photoacoustic imaging, ultrasound-guided thermal ablation is at the forefront of precision treatment of HCC, achieving long-lasting development and developing into a more minimally invasive, accurate, safe, and effective diagnostic and therapeutic mode.
- Carcinoma, Hepatocellular,
- Ablation Techniques,
- Ultrasound,
- Multimodal Image Fusion,
- Photoacoustic Imaging

FullText(HTML)

【据Journal of Viral Hepatitis 2021年4月报道】题：直接抗病毒药物根除HCV后使肝纤维化快速和显著的改善(作者Kang Q等)

目前，关于HCV根除后肝纤维化变化的相关研究数据有限。该研究探讨了HCV根除后肝脏硬度值、APRI、FIB-4、壳多糖酶3样蛋白1及高尔基体蛋白73水平的变化。

该研究纳入了2017年12月—2019年6月在北京大学第一医院感染疾病科经直接抗病毒药物(DAA)治疗的102例慢性丙型肝炎患者。在基线、治疗结束、治疗结束后第12周、24周及48周收集患者的临床信息和血清样本。

102例入组患者中，51例为轻度至中度纤维化，51例为进展期肝纤维化及肝硬化。与基线相比，102例患者肝脏硬度值中位数在治疗结束时下降了2.85 kPa，且持续下降至治疗结束后第12周。其中，51例进展期肝纤维化及肝硬化患者肝脏硬度值中位数变化更显著：与基线水平相比，治疗结束时降低了3.6 kPa；同时，与基线相比，102例患者APRI和FIB-4评分的中位数在治疗结束时均显著下降[0.64(0.39~1.21) vs 0.35(0.26~0.52)，P＜0.001; 2.53(1.30~3.91) vs 1.87(0.89~2.5), P＜0.001]，且持续下降至治疗结束后第12周，但与治疗结束时相比，差异无统计学意义；此外，与基线相比，102例患者的血清壳多糖酶3样蛋白1和高尔基体蛋白73水平在治疗结束时均显著降低[134.07(154.49) vs 103.75(98.04)，P=0.025; 98.24(64.76) vs 88.91 (50.89), P=0.002]。

该研究提示，DAA可显著改善慢性丙型肝炎患者的肝纤维化，表现为肝脏硬度值、APRI及FIB-4评分降低。此外，DAA可降低进展期肝纤维化及肝硬化患者血清壳多糖酶3样蛋白1及高尔基体蛋白73水平，提示壳多糖酶3样蛋白1和高尔基体蛋白73可作为监测慢性丙型肝炎患者肝纤维化的无创血清学标志物。

摘译自KANG Q, XU J, LUO H, et al. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication[J]. J Viral Hepat, 2021, 28(9): 1284-1292. DOI: 10.1111/jvh.13558.

(北京大学第一医院感染疾病科亢倩徐小元报道)

References(41)

References

[1]	VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380: 1450-1462. DOI: 10.1056/NEJMra1713263
[2]	ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1
[3]	XIE DY, REN ZG, ZHOU J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: Updates and insights[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463. DOI: 10.21037/hbsn-20-480
[4]	Global Burden of Disease Liver Cancer Collaboration, AKINYEMIJU T, ABERA S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691. DOI: 10.1001/jamaoncol.2017.3055
[5]	LIANG P, YU J, YU XL, et al. Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: A multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China[J]. Gut, 2012, 61(7): 1100-1101. DOI: 10.1136/gutjnl-2011-300975
[6]	CHEN Z, XIE H, HU M, et al. Recent progress in treatment of hepatocellular carcinoma[J]. Am J Cancer Res, 2020, 10(9): 2993-3036. http://www.researchgate.net/publication/346262415_Recent_progress_in_treatment_of_hepatocellular_carcinoma
[7]	LIANG P, DONG B, YU X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation[J]. Radiology, 2005, 235(1): 299-307. DOI: 10.1148/radiol.2351031944
[8]	YU J, YU XL, HAN ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase Ⅲ randomised controlled trial[J]. Gut, 2017, 66(6): 1172-1173. DOI: 10.1136/gutjnl-2016-312629
[9]	LIU W, ZHENG Y, HE W, et al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: A propensity score analysis[J]. Aliment Pharmacol Ther, 2018, 48(6): 671-681. DOI: 10.1111/apt.14929
[10]	ROSSI S, FORNARI F, BUSCARINI L. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma[J]. J Intervent Radiol, 1993, 8: 97-103. http://ci.nii.ac.jp/naid/10005251016
[11]	SEKI T, WAKABAYASHI M, NAKAGAWA T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma[J]. Cancer, 1994, 74(3): 817-825. DOI: 10.1002/1097-0142(19940801)74:3<817::AID-CNCR2820740306>3.0.CO;2-8
[12]	TSUKAMOTO M, YAMASHITA YI, IMAI K, et al. Long-term favorable outcomes of radiofrequency ablation for hepatocellular carcinoma as an initial treatment: A single-center experience over a 10-year period[J]. Anticancer Res, 2018, 38(2): 1047-1052. http://www.ncbi.nlm.nih.gov/pubmed/29374739
[13]	LIANG P, YU J, LU MD, et al. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy[J]. World J Gastroenterol, 2013, 19(33): 5430-5438. DOI: 10.3748/wjg.v19.i33.5430
[14]	LORENTZEN T, NOLSOE CP, EWERTSEN C, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part I. General Aspects (Short Version)[J]. Ultraschall Med, 2015, 36(5): 464-472. DOI: 10.1055/s-0035-1553601
[15]	LORENTZEN T, NOLSOE CP, EWERTSEN C, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part I. General Aspects (long Version)[J]. Ultraschall Med, 2015, 36(5): e1-e14. DOI: 10.1055/s-0035-1553593.pdf
[16]	NOLSØE CP, NOLSØE AB, KLUBIEN J, et al. Use of ultrasound contrast agents in relation to percutaneous interventional procedures: A systematic review and pictorial essay[J]. J Ultrasound Med, 2018, 37(6): 1305-1324. DOI: 10.1002/jum.14498
[17]	LIU F, YU X, LIANG P, et al. Contrast-enhanced ultrasound-guided microwave ablation for hepatocellular carcinoma inconspicuous on conventional ultrasound[J]. Int J Hyperthermia, 2011, 27(6): 555-562. DOI: 10.3109/02656736.2011.564262
[18]	CHAN AK, HEGARTY C, KLASS D, et al. The role of contrast-enhanced ultrasound in guiding radiofrequency ablation of hepatocellular carcinoma: A retrospective study[J]. Can Assoc Radiol J, 2015, 66(2): 171-178. DOI: 10.1016/j.carj.2014.11.005
[19]	PARK HS, KIM YJ, YU MH, et al. Real-time contrast-enhanced sonographically guided biopsy or radiofrequency ablation of focal liver lesions using perflurobutane microbubbles (sonazoid): Value of Kupffer-phase imaging[J]. J Ultrasound Med, 2015, 34(3): 411-421. DOI: 10.7863/ultra.34.3.411
[20]	FRANCICA G, MELONI MF, DE SIO I, et al. Biopsy of liver target lesions under contrast-enhanced ultrasound guidance - A multi-center study[J]. Ultraschall Med, 2018, 39(4): 448-453. DOI: 10.1055/s-0043-122496
[21]	FRANCICA G, MELONI MF, RICCARDI L, et al. Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study[J]. Eur J Radiol, 2018, 105: 96-101. DOI: 10.1016/j.ejrad.2018.05.030
[22]	MASUZAKI R, SHⅡNA S, TATEISHI R, et al. Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2011, 26(4): 759-764. DOI: 10.1111/j.1440-1746.2010.06559.x
[23]	DIETRICH CF, NOLSOE CP, BARR RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS[J]. Ultrasound Med Biol, 2020, 46(10): 2579-2604. DOI: 10.1016/j.ultrasmedbio.2020.04.030
[24]	LI X, XU M, LIU M, et al. Contrast-enhanced ultrasound-guided feeding artery ablation as add-on to percutaneous radiofrequency ablation for hypervascular hepatocellular carcinoma with a modified ablative technique and tumor perfusion evaluation[J]. Int J Hyperthermia, 2020, 37(1): 1016-1026. DOI: 10.1080/02656736.2020.1811902
[25]	MAURI G, PORAZZI E, COVA L, et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: Clinical impact and health technology assessment[J]. Insights Imaging, 2014, 5(2): 209-216. DOI: 10.1007/s13244-014-0315-7
[26]	XU E, LONG Y, LI K, et al. Comparison of CT/MRI-CEUS and US-CEUS fusion imaging techniques in the assessment of the thermal ablation of liver tumors[J]. Int J Hyperthermia, 2019, 35(1): 159-167. http://www.ncbi.nlm.nih.gov/pubmed/30300032
[27]	MINAMI Y, NISHIDA N, KUDO M. Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRI[J]. World J Gastroenterol, 2014, 20(15): 4160-4166. DOI: 10.3748/wjg.v20.i15.4160
[28]	MELONI MF, FRANCICA G, CHIANG J, et al. Use of contrast-enhanced ultrasound in ablation therapy of HCC: Planning, guiding, and assessing treatment response[J]. J Ultrasound Med, 2020.[Online ahead of print]
[29]	TOWNSEND DW, WENSVEEN M, BYARS LG, et al. A rotating PET scanner using BGO block detectors: Design, performance and applications[J]. J Nucl Med, 1993, 34(8): 1367-1376. http://www.ncbi.nlm.nih.gov/pubmed/8326401
[30]	RHIM H, LEE MH, KIM YS, et al. Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas[J]. AJR Am J Roentgenol, 2008, 190(5): 1324-1330. DOI: 10.2214/AJR.07.2970
[31]	LEE MW, LIM HK, KIM YJ, et al. Percutaneous sonographically guided radio frequency ablation of hepatocellular carcinoma: Causes of mistargeting and factors affecting the feasibility of a second ablation session[J]. J Ultrasound Med, 2011, 30(5): 607-615. DOI: 10.7863/jum.2011.30.5.607
[32]	LIU FY, YU XL, LIANG P, et al. Microwave ablation assisted by a real-time virtual navigation system for hepatocellular carcinoma undetectable by conventional ultrasonography[J]. Eur J Radiol, 2012, 81(7): 1455-1459. DOI: 10.1016/j.ejrad.2011.03.057
[33]	SONG KD, LEE MW, RHIM H, et al. Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: Technical feasibility and therapeutic outcomes[J]. Radiology, 2018, 288(3): 878-886. DOI: 10.1148/radiol.2018172743
[34]	IYER RS, TIMM BA, MITSUMORI LM, et al. Image fusion as a new postprocessing method to evaluate the radiofrequency ablation zone after treatment of malignant liver tumors[J]. J Comput Assist Tomogr, 2010, 34(2): 226-228. DOI: 10.1097/RCT.0b013e3181c4f797
[35]	NUMATA K, FUKUDA H, MORIMOTO M, et al. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma[J]. Eur J Radiol, 2012, 81(10): 2746-2753. DOI: 10.1016/j.ejrad.2011.11.052
[36]	ZHONG-ZHEN S, KAI L, RONG-QIN Z, et al. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma[J]. Ultraschall Med, 2012, 33(7): e250-e255. DOI: 10.1055/s-0032-1325466
[37]	CHENG Q, QIAN ML. Progresses of multi-modality photoacoustic molecular imaging[J]. Appl Acoust, 2018, 37(5): 645-654. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYSN201805008.htm 程茜, 钱梦騄. 多模态光声分子成像进展[J]. 应用声学, 2018, 37(5): 645-654. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSN201805008.htm
[38]	ZHANG XJ, WANG QD, LIAN YZ. Albumin-based SPECT/photoacoustic dual-modality nanoprobe in liver imaging[J]. Chin J Med Imaging, 2017, 25(10): 729-733. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYZ201710004.htm 张晓洁, 王庆大, 连云宗. SPECT/光声双模态纳米探针在肝成像中的应用[J]. 中国医学影像学杂志, 2017, 25(10): 729-733. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYZ201710004.htm
[39]	ZHOU Q, LI Z, ZHOU J, et al. In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft[J]. Photoacoustics, 2016, 4(2): 43-54. DOI: 10.1016/j.pacs.2016.04.001
[40]	GUAN TP. The synthesis of photoacoustic-flurescence dual modality imaging probe based on Au nanorods and application in liver cancer[D]. Guangzhou: Southern Medical University, 2017. (in Chinese) 关天培. 基于金纳米棒的光声-荧光双模分子探针的制备及其在肝癌中的应用[D]. 广州: 南方医科大学, 2017.
[41]	LI Q, CHEN K, HUANG W, et al. Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma[J]. Cancer Lett, 2021, 496: 169-178. DOI: 10.1016/j.canlet.2020.09.024

Relative Articles

[1]	Kaifu LI, Yongcheng TANG, Hao TANG, Xi ZHANG, Benjian GAO, De LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of three-dimensional visualization technology in assisting ablation therapy for hepatocellular carcinoma： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1397-1403. doi: 10.12449/JCH240718
[2]	Baiyu JI, Fenlin HAO, Jiangtao HAI, Junsheng ZHANG, Xiangyang WU, Dong JIN, Zhenhui LU. A prognostic analysis of transcatheter arterial chemoembolization combined with local ablation in treatment of recurrent liver cancer after surgery[J]. Journal of Clinical Hepatology, 2022, 38(7): 1572-1576. doi: 10.3969/j.issn.1001-5256.2022.07.021
[3]	Caixia HU, Peng ZHAO, Bojun LIU, Jiasheng ZHENG, Yonghong ZHANG. Treatment of unresectable periampullary carcinoma with irreversible electroporation: A case report[J]. Journal of Clinical Hepatology, 2022, 38(10): 2344-2345. doi: 10.3969/j.issn.1001-5256.2022.010.027
[4]	Jun LING, Wenwu WAN, Zheng ZENG, Huihua YAO, Ou JIANG, Bing DING. Clinical effect of transcatheter arterial chemoembolization combined with microwave ablation versus repeat resection in treatment of recurrent hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2053-2060. doi: 10.3969/j.issn.1001-5256.2022.09.020
[5]	Rong HE, Zhe JIA, Li JIANG, Ke ZHANG. Application of the three-dimensional visualization ablation planning system in radiofrequency ablation for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2046-2052. doi: 10.3969/j.issn.1001-5256.2022.09.019
[6]	Wen LUO, Jun TIE. Advances in local ablation therapy for liver cancer with portal hypertension[J]. Journal of Clinical Hepatology, 2021, 37(3): 515-521. doi: 10.3969/j.issn.1001-5256.2021.03.005
[7]	Minjun LI, Zhujian DENG, Haotian LIU, Yuxian TENG, Rongrui HUO, Xiumei LIANG, Bangde XIANG, Lequn LI, Jianhong ZHONG. Clinical effect of re-hepatic resection versus radiofrequency ablation in treatment of recurrent hepatocellular carcinoma in Asia: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1103-1109. doi: 10.3969/j.issn.1001-5256.2021.05.025
[8]	Yurong ZHANG, Xiaodong WANG, Xiaoning ZHU, Jing WANG. Research advances in diaphragmatic hernia after thermal ablation for primary liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(12): 2939-2942. doi: 10.3969/j.issn.1001-5256.2021.12.043
[9]	Yaoping SHI, Bo ZHAI. Local treatment of liver cancer: Ablation or resection?[J]. Journal of Clinical Hepatology, 2021, 37(3): 506-509. doi: 10.3969/j.issn.1001-5256.2021.03.003
[10]	Fei CAO, Weijun FAN. Ablation therapy for large hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 501-505. doi: 10.3969/j.issn.1001-5256.2021.03.002
[11]	Ting WANG, Chunyan WANG, Jianyong LIU, Yonghe ZHOU, Wei LU, Jia LI, Li ZHOU. Effectiveness and safety of ultrasound-guided ablation in treatment of primary liver cancer in dangerous areas[J]. Journal of Clinical Hepatology, 2021, 37(7): 1594-1598. doi: 10.3969/j.issn.1001-5256.2021.07.023
[12]	Yan FU, Xiao LI, Xiaowu ZHANG, Jiawei CAO. Management of ablation techniques for liver cancer and establishment of a diverse team for liver cancer ablation[J]. Journal of Clinical Hepatology, 2021, 37(3): 497-500. doi: 10.3969/j.issn.1001-5256.2021.03.001
[13]	Cai MiaoTian, Liang LianChun. Pathogen distribution and drug resistance in liver cancer patients with liver abscess after transarterial chemoembolization or ablation[J]. Journal of Clinical Hepatology, 2020, 36(1): 118-122. doi: 10.3969/j.issn.1001-5256.2020.01.026
[14]	Tang JinQuan, He Pan, Su Song, Luo Bin, Fang Cheng, Li Bo, Xia XianMing, Li YuWei. Short-and long-term effects of radiofrequency ablation versus minimally invasive hepatectomy in treatment of small hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 358-362. doi: 10.3969/j.issn.1001-5256.2020.02.025
[15]	Zhou ChuanLi, Tian ShiChao, Chen XiaoLi, Huang Jin, Zhang XianPing, Zhang XueYan, Xu YaJi. Clinical effect of microwave ablation combined with transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma with portal vein tumor thrombus and related influencing factors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2220-2224. doi: 10.3969/j.issn.1001-5256.2019.10.018
[16]	Xiang Jiao, Jia XiaoDong, Lu ShanShan, Wu DaWei, Zhang Ting, Dong JinKe, Huang JiaGan, Li YinYin, Yang Bin, Xu Yong, Dong Zheng, Lu Ying, Zeng Zhen, Lu YinYing. Effect of cryoablation versus microwave ablation on clinical indices and cytokines in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(8): 1728-1733. doi: 10.3969/j.issn.1001-5256.2019.08.016
[17]	Zhou YanXian, Feng Hui, Dong Zheng, Chen Xia, Li Meng, Zhang XinLi, Tian JiangKe, Su Ying. Analysis of cirrhotic nodules with ultrasound[J]. Journal of Clinical Hepatology, 2010, 26(1): 42-43.
[18]	Li DianQiu, Mao YongXia, Liu ShuJun. The analysis of ultrasonography diagnosis on obstructive jaundice.[J]. Journal of Clinical Hepatology, 2008, 24(4): 268-269.
[20]	Yang SongQing, Wang XiaoCong. Sonographic differentiating the diffuse liver cancer from portal cirrhosis[J]. Journal of Clinical Hepatology, 2001, 17(4): 246-247.

Supplements(0)

Cited By

Cited by

Periodical cited type(1)

严茜，万彬，赵霞，吴春陶，苏丹，曾艳，杨文璐，谢鹏. 雷迪帕韦—索非布韦治疗丙型肝炎肝硬化患者有效性及安全性的Meta分析. 临床合理用药. 2025(03): 21-25+35 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1417) PDF downloads(127)

Current status and advances in ultrasound-guided thermal ablation for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.03.004